Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose esmolol in mitral valve surgery for mitral regurgitation
2018-000680-93Phase 3Terminated
- Sponsor
- Humanitas Research Hospital
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in mitral regurgitation (MR) and low cardiac output syndrome (LCOS) comparing High-dose esmolol infusion with Placebo infusion (2 arms). Primary endpoints: Myocardial protection biomarkers and Incidence of postoperative low cardiac output syndrome. Started Jan 2021; status: terminated.
02
Drugs
esmolol
03
Conditions
mitral regurgitation (MR)low cardiac output syndrome (LCOS)
Beyond the preview
Go deeper on 2018-000680-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000680-93.